Texas Permanent School Fund Corp Sells 586 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Texas Permanent School Fund Corp cut its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,120 shares of the company’s stock after selling 586 shares during the quarter. Texas Permanent School Fund Corp’s holdings in Harmony Biosciences were worth $848,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Quest Partners LLC boosted its position in shares of Harmony Biosciences by 242.1% during the 2nd quarter. Quest Partners LLC now owns 15,034 shares of the company’s stock worth $454,000 after purchasing an additional 10,639 shares in the last quarter. LSV Asset Management raised its stake in Harmony Biosciences by 72.5% during the 2nd quarter. LSV Asset Management now owns 578,246 shares of the company’s stock worth $17,446,000 after buying an additional 243,100 shares during the period. Victory Capital Management Inc. boosted its holdings in Harmony Biosciences by 54.1% in the second quarter. Victory Capital Management Inc. now owns 84,964 shares of the company’s stock worth $2,563,000 after acquiring an additional 29,816 shares in the last quarter. Versor Investments LP acquired a new stake in Harmony Biosciences in the second quarter valued at approximately $549,000. Finally, nVerses Capital LLC acquired a new stake in Harmony Biosciences in the second quarter valued at approximately $36,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

NASDAQ HRMY opened at $39.29 on Friday. The company has a fifty day moving average price of $35.22 and a 200-day moving average price of $32.25. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 0.75 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.13 and a quick ratio of 3.09. Harmony Biosciences Holdings, Inc. has a 1 year low of $18.61 and a 1 year high of $39.73.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The business had revenue of $172.80 million during the quarter, compared to the consensus estimate of $172.53 million. During the same period in the prior year, the firm posted $0.56 EPS. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HRMY shares. Citigroup initiated coverage on Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price on the stock. UBS Group began coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a report on Thursday, September 12th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.